Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCX-102
- Development stage
- Preclinical
- Lead developer
- BlueSphere Bio
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
TCX-102 is an investigational autologous T cell therapy program developed by BlueSphere Bio, focused on the treatment of high-risk leukemias. The program specifically aims to identify and utilize T cell receptors (TCRs) directed against driver mutations in the NPM1 gene, which are present in approximately 30% of acute myeloid leukemia (AML) patients. Unlike related programs that are used in transplant settings, TCX-102 is designed for use in a non-transplant setting. The broader platform technology (TCXpress) enables the capture of TCRs from any T cell and may be applicable to other therapeutic areas such as solid tumors[9].
02
Targets
NPM1 (Nucleophosmin)
Beyond the preview
Go deeper on TCX-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCX-102.